Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

Bibliographic Details
Main Authors: David Muccino, George Philip, A.H. Morice, S.S. Birring, L. Mcgarvey, P.V. Dicpinigaitis, I.D. Pavord, A.M. Tershakovec, M.M. Kitt, C. Assaid, J.A. Smith
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:World Allergy Organization Journal
Online Access:http://www.sciencedirect.com/science/article/pii/S193945512030106X
id doaj-9675d58a5c2d4aa6a7bda944be7a50c6
record_format Article
spelling doaj-9675d58a5c2d4aa6a7bda944be7a50c62020-11-25T03:38:21ZengElsevierWorld Allergy Organization Journal1939-45512020-08-01138100203Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic coughDavid Muccino0George Philip1A.H. Morice2S.S. Birring3L. Mcgarvey4P.V. Dicpinigaitis5I.D. Pavord6A.M. Tershakovec7M.M. Kitt8C. Assaid9J.A. Smith10Merck & Co., Inc., Kenilworth, United StatesMerck & Co., Inc., Kenilworth, United StatesHull York Medical School, Cottingham, United KingdomKing's College London, London, United KingdomQueen's University Belfast, Belfast, United KingdomAlbert Einstein College of Medicine, Bronx, United States; Montefiore Medical Center, Bronx, United StatesUniversity of Oxford, Oxford, United KingdomMerck & Co., Inc., Kenilworth, United StatesMerck & Co., Inc., Kenilworth, United StatesMerck & Co., Inc., Kenilworth, United StatesUniversity of Manchester, Manchester, United Kingdomhttp://www.sciencedirect.com/science/article/pii/S193945512030106X
collection DOAJ
language English
format Article
sources DOAJ
author David Muccino
George Philip
A.H. Morice
S.S. Birring
L. Mcgarvey
P.V. Dicpinigaitis
I.D. Pavord
A.M. Tershakovec
M.M. Kitt
C. Assaid
J.A. Smith
spellingShingle David Muccino
George Philip
A.H. Morice
S.S. Birring
L. Mcgarvey
P.V. Dicpinigaitis
I.D. Pavord
A.M. Tershakovec
M.M. Kitt
C. Assaid
J.A. Smith
Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough
World Allergy Organization Journal
author_facet David Muccino
George Philip
A.H. Morice
S.S. Birring
L. Mcgarvey
P.V. Dicpinigaitis
I.D. Pavord
A.M. Tershakovec
M.M. Kitt
C. Assaid
J.A. Smith
author_sort David Muccino
title Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough
title_short Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough
title_full Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough
title_fullStr Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough
title_full_unstemmed Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough
title_sort rationale and design of two, phase 3, randomized controlled trials (cough-1 and cough-2) of gefapixant, a p2x3 receptor antagonist, in refractory and unexplained chronic cough
publisher Elsevier
series World Allergy Organization Journal
issn 1939-4551
publishDate 2020-08-01
url http://www.sciencedirect.com/science/article/pii/S193945512030106X
work_keys_str_mv AT davidmuccino rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
AT georgephilip rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
AT ahmorice rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
AT ssbirring rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
AT lmcgarvey rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
AT pvdicpinigaitis rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
AT idpavord rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
AT amtershakovec rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
AT mmkitt rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
AT cassaid rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
AT jasmith rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough
_version_ 1724542657984724992

Similar Items